True North Therapeutics Secures $40,000,000 Series C Financing Round

  • Feed Type
  • Date
  • Company Name
    True North Therapeutics
  • Mailing Address
    951 Gateway Blvd. South San Francisco, CA 94080 USA
  • Company Description
    True North Therapeutics is a pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need. The company’s lead monoclonal antibody, TNT009, targets the Classical Complement pathway, enabling selective inhibition of downstream phagocytosis, inflammation, and cell lysis.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series C
  • Proceeds Purposes
    Proceeds from the financing will be used to advance the clinical development of its lead complement inhibitor, TNT009, for Cold Agglutinin Disease (CAD), as well as other rare diseases targeting the Complement system.
  • M&A Terms
  • Venture Investor
    New Leaf Venture Partners
  • Venture Investor
    Perceptive Advisors
  • Venture Investor
    Cowen Capital Partners
  • Venture Investor
    Kleiner Perkins Caufield & Byers
  • Venture Investor
    MPM Capital
  • Venture Investor
  • Venture Investor
    SR One
  • Venture Investor
    Baxalta Ventures

Trending on Xconomy